The Skyactiv-X engine will arrive in 2019.
NYS Entity Status
NYS Filing Date
MARCH 20, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2014 - ENGINEERED INJECTION MOLDING CONSULTING, LLC
2014 - ENGINEERED INJECTION MOULDING CONSULTING, LLC
AROUND THE WEB
- Mazda Will Bring the First Compression Injection Gasoline Engine to Market
By Jack Stewart - Wednesday Aug 9, 2017
- Women of Sex Tech, Unite
By ANNA NORTH - Friday Aug 18, 2017
- Four Credit Repair Agencies Accused Of Misleading Customers, Charging Illegal Fees
By Ashlee Kieler - Tuesday Jun 27, 2017
Four different “credit repair” operations have been ordered to pay a total of more than $2 million in penalties for allegedly tricking people into thinking their bad credit could be easily fixed.The Consumer Financial Protection Bureau announced today that it filed complaints and proposed judgments against Prime Credit, LLC, IMC Capital, LLC, Commercial Credit Consultants, and Park View Law, …
- Neighborhoods That Play Hard to Get
By STEFANOS CHEN - Friday Aug 11, 2017
In some New York neighborhoods, the housing stock is great, but turnover is so low, word of mouth is the best search engine.
- Could the Rockaways Survive Another Sandy?
By LUIS FERRÉ-SADURNÍ - Thursday Jul 13, 2017
Residents are bracing for the worst, wondering whether measures taken so far are enough to keep devastation of the Queens community at bay.
- Painkiller maker stops sales at FDA request because of abuse
By LINDA A. JOHNSON, AP Medical Writer - Thursday Jul 6, 2017
Endo International PLC said Thursday it will voluntarily stop selling the pills, approved for use in patients with severe, constant pain, after consulting with the U.S. Food and Drug Administration.The agency said it had seen a "significant shift" from people crushing and snorting the pill to get high to injecting it instead.Besides contributing to overdoses, abuse of Opana ER was blamed for a 2015 outbreak of HIV and hepatitis C in southern Indiana linked to sharing needles, according to the FDA.Dublin, Ireland-based Endo, which has U.S. headquarters in the Philadelphia suburb of Malvern, said it will work with the FDA to try to minimize disruption for patients, who will need to switch to alternative treatments.